SCHEMBL2089652

SCHEMBL2089652

[CH2]COCc1ccc(OC)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 3/20 0.57
AGXT P21549 2/20 0.57
CA1 P00915 2/20 0.51
CA2 P00918 2/20 0.51
APP P05067 7/20 0.50
ALDH1A1 P00352 1/20 0.50
TP53 P04637 1/20 0.50
CYP3A4 P08684 1/20 0.50
ALOX15 P16050 1/20 0.50
TSHR P16473 1/20 0.50
ALOX12 P18054 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
TDP1 Q9NUW8 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
MAOB P27338 1/20 0.48
CA12 O43570 1/20 0.48
CA7 P43166 1/20 0.48
CA9 Q16790 1/20 0.48
CA14 Q9ULX7 1/20 0.48
CALM1 P0DP23 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5567139 0.86 CA1 (0.45) IDO1AGXTCA1CA2APP
SCHEMBL34413 0.86 IDO1 (0.67) IDO1AGXTCA1CA2APP
SCHEMBL1475481 0.84 IDO1 (0.64) IDO1AGXTCA1CA2APP
Potassium SCHEMBL1477050 0.84 IDO1 (0.64) IDO1AGXTCA1CA2APP
SCHEMBL1838338 0.83 TDP1 (0.54) IDO1AGXTCA1CA2APP
SCHEMBL8499580 0.82 IDO1 (0.61) IDO1AGXTCA1CA2APP
SCHEMBL27455063 0.81 IDO1 (0.67) IDO1AGXTCA1CA2APP
SCHEMBL9022493 0.80 L3MBTL1 (0.59) IDO1AGXTCA1CA2APP
SCHEMBL52777 0.80 IDO1 (0.59) IDO1AGXTCA1CA2APP
SCHEMBL11132720 0.80 LTA4H (0.65) IDO1AGXTCA1CA2APP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-3994939-A BACTERICIDES PFIZER INC. (US) 1976-11-30 US claimed
WO-2023189817-A1 ONIUM SALT, ONIUM SALT COMPOSITION, LIQUID COMPOSITION CONTAINING ONIUM SALT AND POLYSACCHARIDE AND PRODUCTION METHOD THEREOF, AND METHOD FOR RECOVERING POLYSACCHARIDE 広栄化学株式会社 2023-10-05 WO disclosed
EP-2492033-B1 METAL NANOPARTICLE CONTAINING COMPLEX, FLUID DISPERSION THEREOF AND PRODUCTION METHODS FOR METAL NANOPARTICLE CONTAINING COMPLEX AND FLUID DISPERSION THEREOF DAINIPPON INK & CHEMICALS (JP) 2017-03-08 EP disclosed
US-8388870-B2 Metal-nanoparticle-containing composite, dispersion liquid thereof, and methods for producing the metal-nanoparticle-containing composite and the dispersion liquid DIC CORPORATION (JP) 2013-03-05 US disclosed
US-20120280186-A1 METAL-NANOPARTICLE-CONTAINING COMPOSITE, DISPERSION LIQUID THEREOF, AND METHODS FOR PRODUCING THE METAL-NANOPARTICLE-CONTAINING COMPOSITE AND THE DISPERSION LIQUID DIC CORPORATION (JP) 2012-11-08 US disclosed
EP-2492033-A1 METAL NANOPARTICLE CONTAINING COMPLEX, FLUID DISPERSION THEREOF AND PRODUCTION METHODS FOR METAL NANOPARTICLE CONTAINING COMPLEX AND FLUID DISPERSION THEREOF DIC Corporation (JP) 2012-08-29 EP disclosed
US-8163753-B2 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-04-24 US disclosed
US-20100081693-A1 THIADIAZOLE COMPOUND AND USE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-04-01 US disclosed
EP-2061789-A2 THIADIAZOLE COMPOUND AND USE THEREOF Sumitomo Chemical Company, Limited (JP) 2009-05-27 EP disclosed
EP-1678185-B1 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMA CO LTD (JP) 2008-10-08 EP disclosed
EP-0464408-B1 Process for preparing star compounds SEKISUI CHEMICAL CO LTD (JP) 1994-01-12 EP disclosed
US-5266468-A Process for preparing β-hydroxy-α amino acids UNIVERSITY OF NOTRE DAME DU LAC (US) 1993-11-30 US disclosed
EP-0500853-A1 PHENYLETHANOLAMINES, DRUGS CONTAINING THESE COMPOUNDS, AND A METHOD OF PREPARING THEM. THOMAE GMBH DR K (DE) 1992-09-02 EP disclosed
US-5102966-A Addition polymerization of unsaturated ethers using an unsaturated alkenyl polyether adduct as initiator and a cation-donating compound SEKISUI CHEMICAL CO., LTD. (JP) 1992-04-07 US disclosed
WO-1992004316-A1 PHENYLETHANOLAMINES, DRUGS CONTAINING THESE COMPOUNDS, AND A METHOD OF PREPARING THEM DR. KARL THOMAE GMBH (DE) 1992-03-19 WO disclosed
CN-1058046-A The method for preparing beta-hydroxy-a-amino acid UNIV NOTRE DAME DU LAC (US) 1992-01-22 CN disclosed
EP-0464408-A1 Process for preparing star compounds SEKISUI CHEMICAL CO., LTD. (JP) 1992-01-08 EP disclosed
EP-0460883-A2 Process for beta-hydroxy-alpha-amino acids THE UNIVERSITY OF NOTRE DAME DU LAC (US) 1991-12-11 EP disclosed
US-4820815-A USEFUL AS ANTIBACTERIALS OR TO FORM FUSED BICYCLIC B-LACTAM ANTIBIOTICS LIKE CARBAPENEMS UNIVERSITY OF NOTRE DAME DU LAC (US) 1989-04-11 US disclosed
EP-0306266-A1 Azetidinone n-phosphonomethyl esters THE UNIVERSITY OF NOTRE DAME DU LAC (US) 1989-03-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100081693-A1 THIADIAZOLE COMPOUND AND USE THEREOF NR2C2, NR4A3, NR0B2 IDO1 1716/4885AGXT 3155/4885CA1 4105/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.